A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma.

Trial Profile

A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Temozolomide (Primary) ; Carmustine; Cytarabine; Dexamethasone; Etoposide; Rituximab
  • Indications B cell lymphoma; CNS cancer
  • Focus Therapeutic Use
  • Acronyms DRBEAT
  • Most Recent Events

    • 05 Apr 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2019 as per ClinicalTrials.gov record.
    • 05 Apr 2016 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 16 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top